Balsa D, Merlos M, Giral M, Ferrando R, Garcia-Rafanell J, Forn J
Department of Pharmacology, J. Uriach & Cia Laboratories, Barcelona, Spain.
J Lipid Mediat Cell Signal. 1997 Sep;17(1):31-45. doi: 10.1016/s0929-7855(97)00019-9.
The contribution of several vasoactive mediators such as histamine, serotonin, bradykinin, arachidonic acid metabolites and PAF to vascular permeability changes was determined in a rat model of acute endotoxemia. Lipopolysaccharide (10-40 mg/kg, i.v.) from E. coli 0127:B8 (LPS) elicited an increase in Evans blue extravasation in trachea, thymus, seminal vesicle and stomach, whereas other organs remained unaffected. LPS (25 mg/kg)-induced extravasation was not inhibited by intravenous pretreatment with histamine (H1) antagonist mepyramine (5 mg/kg) or bradykinin (B2) antagonist HOE-140 (0.1 mg/kg), whereas other standard drugs selectively inhibited leakage in particular tissues, e.g. the cyclooxygenase inhibitor indomethacin (5 mg/kg) in trachea (78%) and seminal vesicle (64%), the serotonin and H1 antagonists cyproheptadine (2 mg/kg) in trachea (88%) and stomach (56%) and the dual cyclooxygenase/lipoxygenase inhibitor phenidone (10 mg/kg) in seminal vesicle (87%). PAF antagonists lexipafant and UR-12460 (10 mg/kg), but not apafant, potently inhibited extravasation in trachea (59, 84%) and seminal vesicle (81, 78%) and in stomach only UR-12460 (52%), whereas all of them were ineffective in thymus. When extravasation was induced by PAF (4 micrograms/kg) a low dose (0.1 mg/kg) of the three PAF antagonists strongly reduced extravasation in thymus and seminal vesicle, whereas lexipafant and UR-12460 did so in trachea (82, 100%) and only lexipafant in stomach (100%). Mepyramine, cyproheptadine, HOE-140 and indomethacin did not inhibit the effect of PAF, whereas phenidone inhibited it by 58% in trachea. These results suggest that most of the LPS-induced increase in vascular permeability is mediated by secondary vasoactive mediators among which PAF plays a pivotal role, although their relative contribution may vary from tissue to tissue.
在大鼠急性内毒素血症模型中,研究了组胺、5-羟色胺、缓激肽、花生四烯酸代谢产物和血小板活化因子(PAF)等多种血管活性介质对血管通透性变化的影响。来自大肠杆菌0127:B8的脂多糖(LPS,10 - 40 mg/kg,静脉注射)可引起气管、胸腺、精囊和胃中伊文思蓝外渗增加,而其他器官未受影响。LPS(25 mg/kg)诱导的外渗不受组胺(H1)拮抗剂美吡拉敏(5 mg/kg)或缓激肽(B2)拮抗剂HOE - 140(0.1 mg/kg)静脉预处理的抑制,而其他标准药物可选择性抑制特定组织中的渗漏,例如气管(78%)和精囊(64%)中的环氧化酶抑制剂吲哚美辛(5 mg/kg)、气管(88%)和胃(56%)中的5-羟色胺和H1拮抗剂赛庚啶(2 mg/kg)以及精囊(87%)中的双环氧化酶/脂氧合酶抑制剂非那宗(10 mg/kg)。PAF拮抗剂来昔帕泛和UR - 12460(10 mg/kg)可有效抑制气管(59%、84%)和精囊中(81%、78%)的外渗,UR - 12460还可抑制胃中(52%)的外渗,而所有这些拮抗剂对胸腺均无效。当由PAF(4 μg/kg)诱导外渗时,低剂量(0.1 mg/kg)的三种PAF拮抗剂可强烈降低胸腺和精囊中(82%、100%)的外渗,来昔帕泛和UR - 12460可降低气管中(82%、100%)的外渗,只有来昔帕泛可降低胃中(100%)的外渗。美吡拉敏、赛庚啶、HOE - 140和吲哚美辛不抑制PAF的作用,而非那宗可抑制气管中PAF作用的58%。这些结果表明,LPS诱导的血管通透性增加大多由继发性血管活性介质介导,其中PAF起关键作用,尽管它们的相对作用可能因组织而异。